Skip to main content
. 2008 Nov 5;105(45):17420–17425. doi: 10.1073/pnas.0710725105

Fig. 2.

Fig. 2.

Up-regulation of c-myc protein in HeLa cells, U2-OS cells and NHDF cells following RNAi-mediated inhibition of HRPT2 or Paf1 expression. (A) HeLa cells were treated with control siRNA or one of two HRPT2- or Paf1-specific siRNA for 48 h and cells were then subjected to immunoblot analysis using anti-c-myc (Top Panel), anti-parafibromin (Second Panel), anti-Paf1 (Third Panel). (B and C) Based on Western blot analysis as presented in Fig. S7, quantification of c-myc expression was carried out by quantitative ECL and then normalized to actin expression. Significance of the differences were evaluated by Student's t test (***, P < 0.005, **, P < 0.01, *, P < 0.05). (D) U2-OS cells and NHDF cells were treated with control siRNA, HRPT2- or Paf1-specific siRNA as described in Methods. 48 h after treatment, cells were analyzed for expression of c-myc (Top Panel), parafibromin (Second Panel), Paf1 (Third Panel). In A and D the expression of β-actin is shown as a loading control.